T2 Biosystems, Inc. (TTOO)
Stock Price Chart
Key Info
| Market Cap | 248.04M |
| Revenue (ttm) | 9.10M |
| Net Income (ttm) | -58.81M |
| Shares Out | 119.54M |
| EPS (ttm) | -1.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 10, 2020 |
| Last Price | $2.08 |
| Previous Close | $1.70 |
| Change ($) | 0.38 |
| Change (%) | 22.06% |
| Day's Open | 1.74 |
| Day's Range | 1.72 - 2.14 |
| Day's Volume | 31,963,301 |
| 52-Week Range | 0.24 - 3.21 |
More Stats
| Market Cap | 248.04M |
| Enterprise Value | 256.29M |
| Earnings Date (est) | Aug 11, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 119.54M |
| Float | 111.88M |
| EPS (basic) | -1.17 |
| EPS (diluted) | -1.14 |
| FCF / Share | -0.70 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 6.95M |
| Short Ratio | 0.65 |
| Short % of Float | 10.04% |
| Beta | 1.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 27.27 |
| PB Ratio | n/a |
| Revenue | 9.10M |
| Operating Income | -52.06M |
| Net Income | -58.81M |
| Free Cash Flow | -47.87M |
| Net Cash | -8.25M |
| Net Cash / Share | -0.07 |
| Gross Margin | -272.17% |
| Operating Margin | -572.41% |
| Profit Margin | -646.60% |
| FCF Margin | -526.31% |
| ROA | -60.87% |
| ROE | n/a |
| ROIC | -1,624.00% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.34 | 10.50 | 4.67 | 4.08 | 2.81 | 0.12 | 0.27 | 0.02 |
| Revenue Growth | -20.62% | 125.03% | 14.36% | 45.04% | 2263.87% | -55.26% | 1300% | - |
| Gross Profit | -8.43 | -4.90 | -7.36 | -2.79 | 1.07 | 0.12 | 0.27 | 0.02 |
| Operating Income | -52.06 | -45.09 | -53.85 | -50.88 | -43.38 | -30.68 | -19.69 | -14.65 |
| Net Income | -59.01 | -51.15 | -62.43 | -54.80 | -45.29 | -31.39 | -20.61 | -14.46 |
| Shares Outstanding | 45.51 | 40.56 | 32.13 | 26.02 | 20.50 | 8.67 | 1.40 | 1.36 |
| Earnings Per Share | -1.30 | -1.26 | -1.94 | -2.11 | -2.21 | -4.15 | -19.72 | -13.86 |
| Operating Cash Flow | -45.36 | -40.14 | -47.72 | -46.44 | -37.47 | -28.18 | -18.05 | -13.30 |
| Capital Expenditures | -0.76 | -0.59 | -2.48 | -5.49 | -7.97 | -2.08 | -0.51 | -0.28 |
| Free Cash Flow | -46.12 | -40.73 | -50.19 | -51.93 | -45.44 | -30.27 | -18.57 | -13.59 |
| Cash & Equivalents | 11.21 | 50.99 | 42.06 | 73.75 | 73.92 | 73.93 | 30.20 | 9.79 |
| Total Debt | 44.78 | 42.37 | 41.70 | 40.77 | 30.57 | 20.96 | 5.06 | 5.88 |
| Net Cash / Debt | -33.56 | 8.61 | 0.36 | 32.98 | 43.35 | 52.97 | 25.14 | 3.91 |
| Assets | 28.49 | 64.31 | 54.86 | 89.57 | 86.83 | 79.13 | 31.89 | 11.43 |
| Liabilities | 62.49 | 52.92 | 53.52 | 50.23 | 39.89 | 26.13 | 121 | 74.09 |
| Book Value | -34.01 | 11.39 | 1.34 | 39.34 | 46.94 | 53.00 | -89.54 | -62.66 |
Company Profile
Company Details
| Full Name | T2 Biosystems, Inc. |
| Country | United States |
| Employees | 118 |
| CEO | John J. Sperzel |
Stock Information
| Ticker Symbol | TTOO |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: TTOO |
| IPO Date | August 7, 2014 |
Description
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.